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1. Introduction 
 
1.1. Lactic acid bacteria 
Lactic acid bacteria (LAB) consist of a number of bacterial genera within the phylum 
Firmicutes. The genera Carnobacterium, Enterococcus, Lactobacillus, Lactococcus, 
Lactosphaera, Leuconostoc, Melissococcus, Oenococcus, Pediococcus, Streptococcus, 
Tetragenococcus, Vagococcus and Weissella are recognized as LAB (Ercolini et al., 2001; 
Jay, 2000; Holzapfel et al., 2001; Stiles and Holzapfel, 1997). Lactic acid-producing 
Gram-positive bacteria but belonging to the phylum Actinobacteria are genera such as 
Aerococcus, Microbacterium, and Propionibacterium (Sneath and Holt, 2001) as well as 
Bifidobacterium (Gibson and Fuller, 2000; Holzapfel et al., 2001). Members of LAB share 
the property of being Gram-positive bacteria (Fooks et al., 1999) that ferment 
carbohydrates into energy and lactic acid (Jay, 2000). Depending on the organism, 
metabolic pathways differ when glucose is the main carbon source: homofermentative 
bacteria such as Lactococcus and Streptococcus yield two lactates from one glucose 
molecule, whereas the heterofermentative (ie. Leuconostoc and Weissella) transform a 
glucose molecule into lactate, ethanol and carbon dioxide (Caplice and Fitzgerald, 1999; 
Jay, 2000; Kuipers et al., 2000). In addition, LAB produce small organic compounds that 
give the aroma and flavor to the fermented product (Caplice and Fitzgerald, 1999).  
 
The taxonomy of LAB based on comperative 16S ribosomal RNA (rRNA) sequencing 
analysis has revealed that some taxa generated on the basis on phenotypic features do not 
correspond with the phylogenetic relations. Molecular techniques, especially polymerase 
chain reaction (PCR) based methods, such as rep-PCR fingerprinting and restriction 
fragment length polymorphism (RFLP) as well as pulse-field gel electrophoresis (PFGE), 
are regarded important for specific characterization and detection of LAB strains (Gevers 
et al., 2001; Holzapfel et al., 2001). Recently, culture-independent approaches have been 
applied for the detection of intestinal microbiota (Zoetendal et al., 2002). Denaturing 
gradient gel electrophoresis (DGGE) and temperature gradient gel electrophoresis 
(TGGE) analysis of faecal 16S rDNA gene and its rRNA amplicons have shown to be 
powerful approaches in determining and monitoring the bacterial community in faeces 
(Zoetendal et al., 1998).  
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Fig 1. Consensus tree based on comparative analysis of the 16S rRNA gene, showing the 
major phylogenetic groups of lactic acid bacteria with low mol% of guanine plus cytosine 
in the DNA and the nonrelated Gram-positive genera Bifidobacterium and 
Propionibacterium (Holzapfel et al., 2001). 
 
 
 
LAB were first isolated from milk (Carr et al., 2002; Metchnikoff, 1908; Sandine et al., 
1972) and have since been found in such foods and fermented products as meat, milk 
products, vegetables, beverages and bakery products (Aukrust and Blom, 1992; Caplice 
and Fitzgerald, 1999; Harris et al., 1992; Gobbetti and Corsetti, 1997; Jay, 2000; Liu, 
2003; Lonvaud-Funel, 2001; O’Sullivan et al., 2002). LAB occur naturally in fermented 
food (Caplice and Fitzgerald, 1999) and have been detected in soil, water, manure and 
sewage (Holzapfel et al., 2001). LAB exist in human (Boris et al., 1998; Carroll et al., 
1979; Eideman and Szilagyi, 1979; Elliott et al., 1991; Martín et al., 2003; Ocaña et al., 
1999; Reid, 2001; Schrezenmeir and de Vrese, 2001) and in animal (Fujisawa and 
Mitsuoka, 1996; Fuller and Brooker, 1974; Gilliland et al., 1975; Klijn et al., 1995; 
Sandine et al., 1972; Schrezenmeir and de Vrese, 2001). However, some LAB are part of 
the oral flora which can cause dental caries (Monchois et al., 1999; Sbordone and 
Bortolaia, 2003). LAB can work as spoilage organisms in foods such as meat, fish and 
beverages (Jay, 2001; Liu, 2003). LAB have been used as a flavoring and texturizing 
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agent as well as a preservative in food for centuries and are now added as starters in food 
(Caplice and Fitzgerald, 1999). LAB, such as lactobacilli, L. lactis, and Streptococcus 
thermophilus, inhibit food spoilage and pathogenic bacteria and preserve the nutritive 
qualities of raw food material for an extended shelf life (Heller, 2001; O’Sullivan et al., 
2002). Recently, the use of metabolites of LAB as biological preservatives in food 
packaging materials has been discussed (Pirttijärvi et al., 2001; Scannell et al., 2000). 
LAB play an important role in processing animal feeds like silage (Aukrust and Blom, 
1992; Driehuis and Oude Elferink, 2000; Holzer et al., 2003). The antimicrobial effect of 
LAB is mainly due to their lactic and organic acid production, causing the pH of the 
growth environment to decrease (Caplice and Fitzgerald, 1999; Kuipers et al., 2000). Low 
pH induces organic acids to become lipid soluble and diffuse through the cell membrane 
into the cytoplasm (Gottschalk, 1988). LAB also produce acetaldehyde, hydrogen 
peroxide, diacetyl, carbon dioxide, polysaccharides and bacteriocins (Caplice and 
Fitzgerald, 1999; de Vuyst and Degeest, 1999; Rodrígues et al., 2003), some of which 
may act as antimicrobials.  
 
 
1.2. Lactic acid bacteria benefiting health  
LAB have been cited to be part of human (Fuller, 1991; Goldin, 1990; Holzapfel et al., 
2001; Reid, 2001; Schrezenmeir and de Vrese, 2001; Sghir et al., 2000) and animal (Batt 
et al., 1991; Benno et al., 1992; Fujisawa and Mitsuoka, 1996; Perdigón et al., 2001; 
Rodríguez et al., 2003; Schrezenmeir and de Vrese, 2001) microbiota. The neonates 
receive their microbiota primarily in labor and later from the environment (Edwards and 
Parrett, 2002; Fuller, 1989; Fuller and Gibson, 1998; Metchnikoff, 1908). LAB and 
bifidobacteria dominate the microbiota of the full-term neonate (Hall et al., 1990), 
especially when breast-fed (Edwards and Parrett, 2002; Lönnerdal, 2000) with a health-
promoting effect on the child (Arici et al., 2004; Boris et al., 1998; Edwards and Parrett, 
2002). Heikkilä and Saris (2003) isolated LAB from human milk. Martín et al. (2003) 
detected Lactobacillus gasseri from breast-feeding mothers and children in pair and 
observed coccoid LAB sharing identical randomly amplified polymorphic DNA (RAPD) 
patterns. Although it is difficult for microbes to establish themselves in an already 
colonized ecosystem (Tannock, 1990), the health impact of microbiota consisting of LAB 
is well documented in humans (Bezkorovainy, 2001; Fooks et al., 1999; Majamaa and 
Isolauri, 1997; Reid et al., 2003) and in animals (Bezkorovainy, 2001; Ehrmann et al., 
2002; Fujisawa and Mitsuoka, 1996; Nurmi and Rantala, 1973). Gut bacteria are 
anticipated to interact with the host, encompassing direct interaction between bacteria and 
host epithelial cells (de Vos et al., 2004). 
 
LAB are regarded as a major group of probiotic bacteria (Collins et al., 1998; 
Metchnikoff, 1908; Schrezenmeir and de Vrese, 2001; Tannock, 1998). The probiotic 
concept has been defined by Fuller (1989) to mean “a live microbial feed supplement 
which beneficially affects the host animal by improving its intestinal microbial balance”. 
Salminen et al. (1999) proposed that probiotics are microbial cell preparations or 
components of microbial cells that have a beneficial effect on the hea lth and well-being of 
the host. Several lactobacilli, lactococci and bifidobacteria are held to be health-benefiting 
bacteria (Rolfe, 2000; Tuohy et al., 2003), but little is known about the probiotic 
mechanisms of gut microbiota (Gibson and Fuller, 2000). LAB constitute an integral part 
of the healthy gastrointestinal (GI) microecology and are involved in the host metabolism 
(Fernandes et al., 1987). Fermentation has been specified as a mechanism of probiotics 
(Gibson and Fuller, 2000; Metchnikoff, 1908). LAB along with other gut microbiota 
ferment various substrates like lactose, biogenic amines and allergenic compounds into 
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short-chain fatty acids and other organic acids and gases (Gibson and Fuller, 2000; 
Gorbach, 1990; Jay, 2000). LAB synthesize enzymes, vitamins, antioxidants and 
bacteriocins (Fernandes et al., 1987; Knorr, 1998). With these properties, intestinal LAB 
constitute an important mechanism for the metabolism and detoxification of foreign 
substances entering the body (Salminen, 1990). The health-promoting effects of LAB are 
strain specific and result in different mechanisms to produce beneficial health impacts 
(Table 1).  
 
LAB have been found to control intestinal disorders, partially due to serum antibodies 
IgG, and secretory IgA and IgM enhancing immune response (Cross, 2002; Grangette et 
al., 2001; Kimura et al., 1997; Link-Amster et al., 1994; Perdigón et al., 1999). Certain 
strains of LAB can intermittently translocate across the intestinal mucosa without causing 
infection (Berg, 1995), thus influencing systemic immune events (Cross, 2002). Evidence 
has been presented that some lactobacilli can directly stimulate the immune system on the 
gut mucosal surface via localized GI tract lymphoid cell foci (Perdigón et al., 1999). 
Morishita et al. (1971) demonstrated that intestinal origin LAB established in the digestive 
tract of germ-free chickens better than did non-intestinal LAB strains. Several reports 
have been made on LAB surviving the GI tract of humans and animals (Drouault et al., 
1999; Klijn et al., 1995; Yuki et al., 1999). A number of mechanisms work to prevent 
harmful bacteria from growing on and attaching to the intestinal epithelium: production 
and secretion of antimicrobial agents such as bacteriocins and organic acids (Fooks et al., 
1999; Reid, 2001), adherence via competition for the binding sites and steric hindrance 
(Bezkorovainy, 2001; Boris et al., 1998; Schrezenmeir and de Vrese, 2001) and barriers 
interfering with pathogens and hence promoting the elimination of harmful bacteria (Boris 
et al., 1998). Boris et al (1998) reported vaginal LAB strains being able to self-aggregate 
in a process mediated by surface proteins or lipoproteins, depending on the strain. In 
addition, strains adhered to vaginal epithelial cells, interferred with other bacteria and 
coaggregated with tested pathogens in vitro. Both aggregation and adhesion may favor the 
vaginal epithelium through the formation of a bacterial film contributing to the exclusion 
of pathogens from the vaginal mucosa (Boris et al., 1998). L. rhamnosus strain GG and L. 
reuteri ING1 have been shown to exhibit disease-specific adhesion to intestinal tissue 
(Ouwehand et al., 2003). Additionally, reports have been published on bacteriocin 
production by some probiotic bacteria targeting pathogenic bacteria in vitro (Elliason and 
Tatini, 1999; O’Sullivan et al., 2002; Ziemer and Gibson, 1998). Reutericyclin, an 
antibiotic produced by Lactobacillus reuteri LTH2584, has recently been discovered to 
inhibit a broad range of bacteria (Gänzle et al., 2000). Its biological activity is comparable 
to that of nisin. The colonized L. reuteri LTH2584 cells were recovered from the intestine 
of reconstituted lactobacilli-free (RLF) mice in high cell counts. This strain is proposed to 
be a valuable tool for studying the role of antibacterial agents in intestinal habitats. 
(Gänzle, 2004).  
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Table 1. Selected health-promoting lactic acid bacteria, their impacts and mechanisms. 
 
Health effect Mechanisms Strain example Reference 
Relieve lactose 
intolerance 
symptoms 
Hydrolysing lactose into 
glucose and galactose 
and forming the physical 
appearance of milk into 
a thick substance, such 
as yogurt, that passes 
through the GI tract 
slowly, reducing the 
lactose pulse in the 
colon. 
Lactobacillus 
rhamnosus GG 
 
Drouault and Corthier, 
2001 
Heyman, 2000 
Hove et al., 1999 
 
Control viral, 
bacterial and 
antibiotic-
associated diarrhea 
in humans and 
animals 
Reinforcing the local 
immune defence through 
specific IgA response to 
rotavirus and pathogens. 
L. rhamnosus 
GG 
L. reuterii 
Enterococcus 
faecium 
Ehrmann et al., 2002 
Heyman, 2000 
Majamaa and Isolauri, 
1997 
Oksanen et al., 1990 
Vahjen and Männer, 
2003 
Prevention of  
allergies and atopic 
eczema 
Prevention is partially 
due to serum antibodies 
IgG and secretory IgA 
and IgM immune 
response enhanced by 
probiotics. 
L. rhamnosus 
GG 
Bifidobacteriu
m lactis Bb-12 
Cross, 2002 
Link-Amster et al., 1994  
Perdigón et al., 1999 
Majamaa and Isolauri, 
1997 
Isolauri et al., 2000 
Prevention of 
intestinal bacterial 
enzymes involved 
in the synthesis of 
colonic 
carcinogens  
Enhancing host’s 
immune response, 
binding and degrading 
carcinogens, producing 
antimutagenic 
compounds, alteration of 
metabolic activities of 
intestinal bacteria and 
alteration of 
physiochemical 
conditions in colon 
might work to prevent 
cancer.  
B. bifidum 
B. infantis 
B. longum 
L. acidophilus 
L. paracasei 
 
Hirayama and Rafter, 
2000 
Rolfe, 2000  
Sanders, 1998 
Inactivation and 
reduction of 
pathogenic bacteria 
Production of 
antimicrobic substances 
and Competitive 
Exclusion (CE).  
Lactococcus 
lactis 
Pediococcus 
acidilactici 
Elliason and Tatini, 
1999 
Nurmi and Rantala, 
1973 
O’Sullivan et al., 2002 
Direct stimulation 
of the immune 
system on the gut 
mucosal surface 
Adherence to 
mammalian extracellular 
matrix. Stimulation via 
localized GI tract 
lymphoid cell foci. 
L. crispatus 
strains 
JCM1132, 
ST1, A33 and 
134mi 
L. gasseri CT5 
L. reuteri CT7 
Edelman et al., 2002 
Toba et al., 1995 
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However, the validity of the probiotic concept has been questioned (Shanahan, 2003; 
Tannock, 2003). The adequate information by which the consumer and health professional 
can judge the efficacy and safety of retailed probiotics is lacking. Probiotic products have 
not been subjected to large scale trials of efficacy that are used in the pharmaceutical 
industry. (Tannock, 2003). As an example, no direct evidence of LAB suppressing colon 
cancer has yet been put forward (Hove et al., 1999). In addition, the difficulty of in vivo 
studies poses problems in further showing the complete effects of probiotics (Shanahan, 
2003). Much remains to be done to understand the full effect of probiotics, given the 
extreme complexity of the biological systems of humans and their interactivity 
(Klaenhammerand Kullen, 1999). Studies conducted on bacteria beneficial to health 
covers only a segment of the human ecosystem (Klaenhammer and Kullen, 1999; 
Shanahan, 2003). In vivo sampling in humans also raises ethical issues limiting the scope 
of physiological and clinical testing. For this reason, alternative methods are implied, such 
as performing mucosal biopsies on specific parts of the GI tract (Shanahan, 2003) and 
detecting selective bacteria from faecal samples (Simmering and Blaut, 2001). The 
stablity of probiotic LAB in the GI tract is another concern. Heilig et al (2002) showed 
that GI tract bacterial biota altered during first five months of an infant’s life, while the 
composition of the Lactobacillus community remained more stable over a two-year study 
on adults, with individual differences. L. lactis may survive in human (Klijn et al., 1995) 
and in mouse (Drouault et al., 1999) GI tract. 
 
 
1.2.1. Bacteriocins produced by lactic acid bacteria 
Some LAB strains ribosomally synthesize antimicrobial peptides, or bacteriocins, targeted 
to inhibit other Gram-positive bacteria (Abee, 1995; Barefoot and Nettles, 1993; Caplice 
and Fitzgerald, 1999; O’Sullivan et al., 2002). Even though antimicrobial peptides occupy 
an inhibition spectrum narrower than that of antibiotics (McAuliffe et al., 2001; Morency 
et al., 2001), bacteriocins produced by LAB have been reported to permeate the outer 
membrane of Gram-negative bacteria and to induce the inactivation of Gram-negative 
bacteria in conjunction with other enhancing antimicrobial environmental factors, such as 
low temperature, organic acid and detergents (Alakomi et al., 2000; Elliason and Tatini, 
1999).  
 
Bacteriocins produced by LAB are classified into three main groups, lantibiotics being the 
most documented and industrially exploited. The groups are lantibiotics (Class I), non-
lantibiotics, small heat-stable peptides (Class II) and large heat-labile protein (Class III) 
(O’Sullivan, et al., 2002). The lantibiotic nisin naturally produced by Lactococcus lactis 
ssp. lactis is commercially available as food additive E234 (Anonymous, 1994). The nisin 
variants A and Z, differing by one amino acid (de Vos et al., 1993), are approved for use 
in foodstuffs by food additive legislating bodies in the US (Food and Drug 
Administration, FDA) and in the EU (Thomas et al., 2000). In addition, a new nisin 
variant, nisin Q, has been isolated from a L. lactis strain found in river water in Japan. 
Nisin Q differs in four amino acids as a mature peptide and in two amino acids of the 
leader sequence. (Zendo et al., 2003). All forms of nisin are antimicrobially active against 
Gram-positive bacteria, such as LAB, Listeria sp., Micrococcus sp. and sporeforming 
bacteria like Bacillus sp. and Clostridium sp. (McAuliffe et al., 2001; Thomas et al., 2000; 
Zendo et al., 2003). The inhibiting mode of nisin towards vegetative cells consists of 
several phases. Nisin accumulates on the cell membrane and inserts into it, then 
aggregates within the membrane to form a water-filled pore (Nissen-Meyer et al., 1992; 
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Thomas et al., 2000; McAuliffe et al., 2001). Another model suggests that nisin molecules 
bind by electrostatic interactions to the anionic membrane surface, leading to a high local 
concentration that disturbs the lipid dynamics and causes localized strains, forcing the 
nisin into the membrane (Driessen et al., 1995). At this stage, a voltage-dependent pore is 
formed leading to the dissipation of the bacterial proton motive force. Loss of the proton 
motive force, required for ATP synthesis and the transport of ions, causes cell death 
through depletion of energy dependent reactions (Breukink and de Kruijff, 1999). Nisin is 
also known to inhibit peptidoglycan biosynthesis by interacting with cell wall precursors, 
lipid I and lipid II (Wiedemann et al., 2004). Breunkink et al. (2003) concluded that nisin-
lipid II interaction stablilized the pore complex. The electric transmembrane potential is 
strongly reduced in the presence of nisin and lipid II (Wiedemann et al., 2004). 
Furthermore, nisin inactivates endospores by preventing post-germination swelling and 
subsequent spore outgrowth (Hitchins et al., 1963; Thomas et al., 2000). 
 
LAB capable of secreting antimicrobial peptides are used in a probiotic manner as food 
preservatives as well as health-promoting agents for humans (Barefoot and Nettles, 1993; 
Ryan et al., 1996; Ocaña et al., 1999; O’Sullivan et al., 2002) and animals (Robredo and 
Torres, 2000; Ryan et al., 1996). Nisin applied as a food preservative extends the shelf life 
of a product (O’Sullivan, et al., 2002; Zottola et al., 1994). It is relatively stable in 
foodstuffs since 15 – 20% of nisin is lost in heat treatment (Thomas et al., 2000). For 
probiotic purposes, bacteriocins are generally produced by a LAB strain in the product 
(Bernet-Camard et al., 1997; Dunne and Shanahan, 2003; Joosten and Nuñez, 1996; Yuki 
et al., 1999). The bacteriocin concentration then remains lower than when the purified 
antimicrobial agent is added.  
 
Bacteria have self-protective mechanisms limiting the bacteriocin production, as in the 
case of nisin-producing Lactococcus lactis (Immonen and Saris, 1998; Kuipers et al., 
1993; Qiao et al., 1995). The bacteriocin production is highest at the end of the 
exponential and early stationary phase (Daba et al., 1993; Thomas et al., 2000) and 
reduction is caused by proteolytic degradation of the bacteriocin (De Vuyst and 
Vandamme, 1994; Thomas et al., 2000). Some bacterial strains, such as Clostridium 
botulinum 169B (Mazzotta and Montville, 1999) and Streptococcus bovis JB1 (Mantovani 
and Russell, 2001) are resistant to nisin. Resistance is assumed to be based on the 
enzymatic decomposition of nisin (Breuer and Radler, 1996). Nisin resistance in spore-
forming strains has been associated with an enzyme produced during germination acting 
on the C-terminal lanthionine ring of nisin (Jarvis, 1967; Mazzotta and Montville, 1999). 
Breuer and Radler (1996) demonstrated that differences in the resistance to nisin among 
Lactobacillus casei strains are related to cell-wall linked heteropolysaccharaides, whereas 
Mantovani and Russell (2001) reported nisin-resistant S. bovis JB1 cells having more 
lipoteichoic acid than nisin-sensitive cells.   
 
 
1.2.2. Effect of prebiotics on probiotic bacteria  
The ability of a probiotic LAB strain to survive in the GI tract may be promoted by 
oligosaccharides facilitating the metabolism and growth of LAB in the lumen (Salminen 
et al., 1998a). Dietary fibre, mainly oligosaccharides and polysaccharides fermented in the 
colon may act as prebiotics (Fooks et al., 1999; Ziemer and Gibson, 1998). The 
importance of prebiotics as enhancers of the growth and performance of probiotic bacteria 
has been documented in humans (Crittenden et al., 2002; Fooks et al., 1999; Van Loo et 
al., 1999). Bifidobacterium sp. and Lactobacillus sp. especially produce a positive effect 
on human health (Gibson and Fuller, 2000; Gmeiner et al., 2000; Schaafsma et al., 1998). 
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The significance of prebiotics in animal diet has also been studied (Hussein et al., 1999) 
and represents a growing field of research (Gibson and Fuller, 2000).  
 
 
1.3. Exploitation of probiotic lactic acid bacteria 
The methods for selection of probiotic bacterial strains are discussed in the literature. Host 
specificity, the generally regarded as safe (GRAS) status, colonization, antimicrobial 
activity, and desirable metabolic activity are generally agreed upon (Collins et al., 1998; 
Reid et al., 2003; Tannock, 1998), but issues such as the effect of living versus nonliving 
probiotics or even their survival in the intestinal tract (Canducci et al., 2000; Reid et al., 
2003) remain open. Criteria for quality, including the sensory characteristics of probiotic 
strains, is well established (O’Sullivan et al., 2002; Reid et al., 2003) as are those for 
technological suitability (Charteris et al., 1998a; Knorr, 1998). In addition to in vitro 
experiments (Charteris et al., 1998b, Gibson and Fuller, 2000), animal models (Borriello, 
1990; Cross, 2002; Mallett et al., 1986) and GI tract simulation studies (Gmeiner, et al., 
2000) have been employed for probiotic detection. The ultimate test for probiotic 
functionality is a double blind, placebo-controlled and randomised human study (Gibson 
and Fuller, 2000). Uses of probiotic LAB are listed in Table 2. Prebiotic and probiotic-
based biotherapy has shown potential as an alternative for medical treatment (Dunne and 
Shanahan, 2003). The demonstration of probiotic activity of a given strain requires a well -
designed, double blind, placebo-controlled host-specific study also showing resistance to 
technological processes, meaning viability and activity throughout processing phases 
(Dunne et al., 2001). Each potential probiotic strain must be documented independently, 
without extrapolating any data from closely related strains and employing only well-
defined strains, products and study populations in trials. Results should be confirmed by 
independent research groups and published in a peer-reviewed journal (Berg, 1998; 
Salminen et al., 1996; Salminen et al., 1998b).  
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Table 2. The probiotic effect of lactic acid bacteria (LAB) in human and animal health.  
 
Medical target Example strain Reference 
Prevent food allergy L. rhamnosus GG Sütas et al., 1996 
Block formation of biogenic amines  L. lactis ESI 561 
E. faecalis INIA 4-07 
E. faecalis EFS 2 
Joosten et al., 1996 
Overcome lactose intolerance  L. acidophilus Gilliland and Kim, 1984 
Prevent diarrhea (antibiotic-
induced, rotavirus, travellers, 
community acquired, Clostridium 
difficile colitis) 
LAB 
L. rhamnosus GG 
L. acidophilus LB 
 
Fooks et al., 1999 
Heyman, 2000  
Oksanen et al., 1990 
Simakachorn et al., 2000 
Sanders, 2003 
Reduce intestinal disorders and 
pouchitis 
LAB  
L. rhamnosus GG 
Gionchetti et al., 2000 
Kuisma et al., 2003 
Suppress side effects of 
Helicobacter pylori medication with 
antibiotics. 
L. acidophilus Canducci et al., 2000 
Treat Crohn’s disease, ulcerative 
colitis and imflammatory bowel 
disease (IBD) 
L. rhamnosus GG 
B. infantis UCC35624 
LAB 
Gupta et al., 2000 
Von Wright et al., 2002 
Marteau et al., 2002 
Stimulate anticarcinogenic activity LAB  
L. acidophilus 
Goldin, 1990 
Hirayma and Rafter, 
2000 
Treat coronary heart disease and 
anticholesterolaemic effects 
L. acidophilus Schaafsma et al., 1998 
Gilliland et al., 1985 
Control of human urinary tract 
infection and vaginosis 
L. rhamnosus GG 
L. rhamnosus GR-1 
Kontiokari et al., 2001 
Reid, 2001 
Reid, 2002 
Prevent kidney stones L. acidophilus 
L. plantarum 
L. brevis 
S. thermophilus 
B. infantis 
Campieri et al., 2001 
Treat atopic disease L. rhamnosus GG Kalliomäki et al., 2001 
Prevent caries formation L. rhamnosus GG Näse et al., 2001 
Protection against tetanus toxin L. plantarum Grangette et al., 2001 
Treat chronic fatigue syndrome LAB Logan et al., 2003 
Inhibit pathogens causing bovine 
mastitis  
L. lactis DPC3147 Ryan et al., 1998 
Feed supplement for growth 
promotion in animals 
L. brevis C10 
 
Jin et al., 1998 
 
Reduce pathogens in chickens by 
Competitive Exclusion (CE) 
Undefined faecal 
cultures 
Nurmi and Rantala, 
1973 
Inhibit enteropathogens in small 
intestine of animals 
L. acidophilus LA1 Bernet-Camard et al., 
1997 
 
LAB = Lactic acid bacteria species not specified.
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1.4. Safety of lactic acid bacteria 
The use of LAB as a probiotic requires a safety assessment. The functional properties of 
the strains should be well studied and documented (Holzapfel et al., 2001). Generally 
recognized health-promoting properties are non-pathogenic behavior, the ability to persist 
within the GI tract and adhesion, and the ability to modulate immune responses (Dunne et 
al., 2001; Gibson and Fuller, 2000; Holzapfel et al., 2001; Reid et al, 2003). Gibson and 
Fuller (2000) pointed out the importance of considering the possible side effects of 
probiotics on the consumer, e.g. bloating or blocking the normal functional gut transit. 
Ishibashi and Yamazaki (2001) pursued the research of bacteria converting food 
components or biological secretions into secondary substances harmful to the host. 
 
Lactobacilli and lactococci commonly hold a GRAS status. Japan legally recognises 
functional foods (Foods for Specified Health Use, FOSHU) (Sanders, 2003). Lethal dose 
(LD50) of LAB was measured for mice by oral administration and found to be > 10
11 
cfu/kg, depending on the strain (Ishibashi and Yamazaki, 2001). The safety of two 
Bifidobacterium longum strains of human origin was evaluated on healthy adult 
volunteers: no side effects were reported and the immune parameters measured remained 
without undesirable changes (Mäkeläinen et al., 2001). However, some enterococci such 
as E. faecalis and E. faecium are classified in risk group II as pathogens (Anonymous, 
2004c). Special concern has been expressed on the potential risk arising from the 
existence of antibiotic transferable genes among lactobacilli (Lindgren, 1999). Some 
species of LAB (L. acidophilus, L. reuteri, L. rhamnosus, Leuconostoc spp.) commonly 
used in the food industry or naturally occuring in raw food materials are resistant to 
glycopeptide antibiotics such as teicoplanin and vancomycin (Felten et al., 1999; 
Goldstein et al., 2000; Tynkkynen et al., 1998; Vescovo et al., 1982). Antibiotic resistance 
encoding genes may transfer into a susceptible strain via a mobile genetic element (Noble 
et al., 1992; Shlaes et al., 1989), such as plasmids (Leclercq et al., 1987; Teuber et al., 
1999; Vescovo et al., 1982) and transposons (Arthur et al., 1993; Hill et al., 1985) to 
produce new resistant bacterial strains (Danielsen and Wind, 2003). Conjugative 
transposons are commonly found in enterococci and streptococci as well as in some 
Lactococcus lactis strains reported to contain a chromosomally located transposon 
(Immonen et al., 1998; Rauch and de Vos, 1992). Plasmids of LAB do not commonly 
carry transmissible antibiotic resistance genes but can take in conjugative transposons and 
plasmids. Some plasmids, such as those with bacteriocin immunity genes, can integrate 
into the chromosome (Rauch and de Vos, 1992; Steele and McKay, 1989). Plasmid-linked 
antibiotic resistance therefore poses a hazard (Lindgren, 1999).  
 
Resistance to glycopeptides in clinical isolates are classified as high-level resistance as 
well by inducibly and constitutively low-level resistance (Quintiliani et al., 1993). 
Vancomycin resistance in enterococci is associated with the presence of nucleotide 
sequences related to vanA (Dutka-Malen et al., 1990), vanB (Hayden et al., 1993) and 
vanC (Quintiliani et al., 1993). Use of feeds containing antibiotics and antibiotics for 
promoting growth in animals, such as fluoroquinolones for poultry, were shown to 
correlate with antibiotic-resistant bacteria in the animals (Teuber et al., 1999; Witte, 
1998). Several Enterococcus strains and some of Lactobacillus spp. (L. casei, L. 
plantarum, L. rhamnosus) with transferable vancomycin resistance have been isolated 
from clinical samples (Cooper et al., 1998; Leclercq et al., 1989; Shlaes et al., 1989), 
indicating that antibiotic medication may be involved in such cases (Shlaes et al., 1989; 
Witte, 1998). Lactobacilli appear to be sensitive to penicillins but less so to oxacillin, 
cefoxitin, ceftriaxone, metronidazole, cephalothin and imipenem (Danielsen and Wind, 
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2003; Goldstein et al., 2000). Low sensitivity to ampicillin and piperacillin has been fully 
observed as well (Goldstein et al., 2000). L. acidophilus and L. reuteri as well as the 
genus Enterococcus are examples of probiotic bacteria (Benyacoub et al., 2001; Vescovo 
et al., 1982) resistant to some degree to vancomycin (Arthur et al., 1993; Leclercq et al., 
1989; Vescovo et al., 1982). 
  
The antibiotic resistance genes serving as selective markers in LAB have been replaced by 
food-grade cloning systems (de Vos, 1999) based on i.a., nisin immunity (Takala and 
Saris, 2002), complementation of deficiency in lactose utilization (Takala et al., 2003), 
and suppression of nonsense mutation (Sørensen et al., 2000) for positive selection of 
transformants. The term food-grade can be used when the modified microorganism 
contains such elements not harming the consumer when present in foods. Food-grade 
cloning systems need to be based on DNA from LAB or other microbes with a long 
history of safe use in the food industry (de Vos, 1999). Genetically modified LAB can in 
future be utilized as improved starters in food fermentation and for the safe production of 
metabolites used as food additives (de Vos, 1999). 
 
The isolation of LAB from clinical samples has raised debate over the safety of probiotic 
bacteria and whether or not the bacteria are actually infectious (Adams and Marteau, 
1995; Felten et al., 1999; Donohue et al., 1998; Ishibashi and Yamazaki, 2001). Some 
LAB have been implicated in local systemic infections including septicemia and 
endocarditis (Antony et al., 1995; Husni et al., 1997; Ishibashi and Yamazaki, 2001; 
Soleman et al., 2003) as well as liver abscesses (Rautio et al., 1999). In most cases of 
infection, the organisms were shown to be of host origin. Some cases have been linked to 
the consumption of probiotics (Salminen et al., 2002; Salminen et al., 2004). Except for 
enterococci and streptococci, the clinical significance of LAB is low (Boulanger et al., 
1991), L. rhamnosus being the most frequently isolated LAB from clinical samples 
(Felten et al. 1999). The isolation of LAB from infections is likely to be the result of 
opportunist pathogens on an immunosuppressed host (Ishibashi and Yamazaki, 2001; 
Salminen et al., 2002). Many factors may promote translocation of intestinal bacteria, 
such as intestinal mucosal injury, immunodeficiency of the host, an abnormal intestinal 
bacterial microbiota (Berg, 1995), previous antibiotic treatment, complications from 
Acquired Immunodeficiency Syndrome (AIDS) and prior hospitalization and surgery 
(Antony et al., 1996; Cooper et al., 1998; Husni et al., 1997).  
 
The development of novel approaches in food (de Vos et al., 1997; Luoma et al., 2001) 
and in pharmaceutoclinical therapies (Grangette et al., 2001; Saavedra, 2001; Steidler, 
2002) allow broadening the potential for using lactic acid bacteria in food and 
pharmacology (Kuipers et al., 2000; Mollet, 1999; Renault, 2002). The nature of genetic 
modifications can be divided into three groups: 1) one-step genetic events like deletions, 
gene amplifications, plasmid insertions and losses, 2) multi-step genetic rearrangements 
with DNA of the same species, and 3) trans-species genetic modifications (Mollet, 1999). 
Kuipers et al. (2000) has emphasized the effective use of gene manipulated LAB in the 
battle against food spoilage and pathogenic bacteria. As examples, genetically modified 
LAB have been utilized to improve cheese ripening (Luoma et al., 2001), produce phage-
resistant starter strains (Moineau, 1999), and protect against tetanus toxin (Grangette et 
al., 2001) and bovine rotavirus (Enouf et al., 2001). It can be used to treat Shiga toxigenic 
Escherichia coli infections and dysentery in humans (Paton et al., 2000), prevent dental 
caries (Hillman, 2002) and treat inflammatory bowel disease (Steidler et al., 2003). 
Netherwood et al., (1999) studied spontaneous gene transfer in the GI tract and observed 
that in vivo transfer rate in the gut was 0.03 transconjugants per recipient cell.  
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All new ingredients and genetically modified organisms (GMO) in foods fall under the 
Novel Foods Regulation of the EU legislation (Feord, 2002; Lindgren, 1999). No GMO 
has yet been authorized as a feed additive in Europe (Anonymous, 2001). Renault (2002) 
discussed the use of genetically engineered LAB in foods, emphasizing the value of risk 
assessment in correlation with the expected benefits of modified strains. The objective of 
risk assessment is to identify and evaluate the potential adverse effects of GMOs. The 
cumulative and long-term effects on human health and the environment have also to be 
taken into account. Assessment focuses on GM development and the possible gene-
transfer to host microbiota. (Renault, 2002). 
 
Since the LAB of human and animal microbiota is regarded safe and is believed to be 
beneficial to the host, this study aims at isolating LAB from human and animal microbiota 
and screening them for potential probiotic use.   
 
  18
 
2. Aims of the study 
 
Humans and animals carry a specific microbiota consisting in part of lactic acid bacteria. 
These LAB are believed to be beneficial to the host. The probiotic effect has been widely 
researched in humans and in rat models. The present study aims at isolating and 
characterizing LAB from human and animal microbiota and charting the possible exploitation 
of such bacteria. The steps taken to reach this objective consist of:   
 
1. Isolation of antagonistic bacteria from human milk.  
2. Determining the potential of human-origin LAB for human protective use.  
3. Selection of electrotransformable LAB from chicken intestine to improve feed 
absorption and chicken health. 
4. Isolation and identification of LAB from canine faeces. Screening for probiotic strains 
for canine health benefits.  
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3. Materials and methods 
 
3.1. Strains and plasmids 
 
Table 3. Strains used in this study. 
 
Strain Studied in 
Paper nr 
Strain origin and reference 
Bacillus licheniformis 553/1  HAMBI, Salkinoja-Salonen et 
al., 1999 
Escherichia coli TG-1 III Genesit Ltd, Sambrook et al., 
1989a 
Lactobacillus crispatus 28mc III This work 
Lactobacillus crispatus 145mc III This work 
Lactobacillus crispatus 29mi III This work 
Lactobacillus crispatus 81mi III This work 
Lactobacillus crispatus 101mi III This work 
Lactobacillus crispatus 119mi III This work 
Lactobacillus crispatus 134mi III Danisco, Edelman et al., 2002 
Lactobacillus crispatus A33 III Danisco, Edelman et al., 2002 
Lactobacillus crispatus ATCC33820 III ATCC, Skerman et al., 1980 
Lactobacillus fermentum LAB8 IV This work 
Lactobacillus mucosae LAB12 IV This work 
Lactobacillus rhamnosus LAB11 IV This work 
Lactobacillus salivarius LAB9 IV This work 
Lactococcus lactis ssp. lactis LL3  I, II This work 
Lactococcus lactis ssp. lactis 310 I This work 
Lactococcus lactis ssp. lactis 2410 I This work 
Lactococcus lactis ssp. lactis 3A I This work 
Lactococcus lactis ssp. lactis 4B I This work 
Lactococcus lactis ssp. lactis 6A I This work 
Lactococcus lactis ssp. lactis 6B I This work 
Lactococcus lactis ssp. lactis N8  I Valio Ltd, Graeffe et al., 1991 
Lactococcus lactis ssp. lactis ATCC11454  I, II ATCC, Schleifer et al., 1985 
Lactococcus lactis ssp. lactis NZ9800 I NIZO, Kuipers et al., 1993  
Lactococcus lactis ssp. lactis LAC240 I Reunanen and Saris, 2003 
Micrococcus luteus A1 NCIMB8166 I, IV ATCC, Hoff et al., 1947 
Weissella confusa LAB10 IV This work 
 
 
Table 4. Plasmids used in this study. 
 
Plasmid Relevant properties Studied in Paper 
nr 
Plasmid origin and reference 
pLEB579  ErmR 2.9 kb III This work 
pLEB580  ErmR 4.2 kb III Takala and Saris, 2002 
pLEB590 Nisin 3.1 kb III Takala and Saris, 2002 
pLEB599  ErmR 7.5 kb III Reunanen and Saris, 2003 
pNZ9111 ErmR 15.4 kb III NIZO, van der Meer et al., 1993 
  
ErmR = Plasmid encodes for erythromysin resistancy 
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3.2. Methods 
 
Table 5. Methods employed in this study.  
 
 Method Description Found in 
Paper nr 
Strain isolation    
 L. lactis strains  M17G growth medium (Oxoid, Unipath Ltd, 
Basingstoke, England) containing 0.5% (w/v) 
glucose 
I, II 
 Non-starter bacteria  Sugar-free peptone agar (FIL-IDF Standard 
method. Anonymous, 1971) 
II, 
 Molds and yeasts Yeast Glucose Chloramphenicol agar (YGC, 
Merck, Darmstadt, Germany) 
II, 
 Coliforms Violet Red Bile agar (VRB, Biokar Diagnostics, 
Lyon, France) 
II, 
 Lactobacillus strains Modified Lactobacillus Selective Medium, mLBS 
(Becton Dickinson Microbiology Systems, 
Cockeysville, MD, USA) without acetic acid. 
III, IV 
 Bacillus licheniformis  Trypticase Soy agar, TSA (Becton Dickinson)  
Identification   
 Partial 16S rRNA gene 
sequencing 
Edwards et al., 1989 
Institute of Biotechnology, University of 
Helsinki, Finland 
I, III, IV 
 Alignment and 
identification data base 
NCBI Blast Library (www.ncbi.nlm.nih.gov) I, III, IV 
 Structural nisin gene 
analysis 
Graeffe et al., 1991 I 
 Riboprinting analysis Pirttijärvi et al., 1999 
RiboPrinterTM Microbial Characterization 
System, Qualicon, DuPont, Wilmington, DE, 
USA 
RiboPrinterTM System Data Analysis Program, 
2000 
Bionumerics, Applied Maths, BVBA, 9830 Sint-
Martens-Latem, Belgium 
I 
 GFP-based nisin 
bioassay 
Reunanen and Saris, 2003 
Fluoroskan Ascent 374 scanning fluorometer 
computer-linked with Ascent version 1.2 software 
(Labsystems, Helsinki, Finland). 
I 
 Metabolic 
characterization 
Biolog manual, Biolog Inc., Hayward, CA, USA 
MicrologTM System, Biolog Inc., Hayward, CA, 
USA 
I 
 Agar diffusion test  Tramer and Fowler, 1964 I, IV 
 Whole cell fatty acid 
analysis 
MIDI Inc., Newark, DE, USA III 
 Growth 
characterization  
 III, IV 
Exploitation   
 Sensory evaluation Pliner and Hobden, 1992, Tuorila et al., 2001 II 
 Electrotransformation Sambrook et al., 1989b III 
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3.2.1. Sample origin and specimen collection 
Samples of human milk (n = 20) were collected during the early lactation period (within 
80 days of birth). The donors were healthy first-time deliverers and mothers with several 
children from southern Finland. Two milk samples were received within a month from 
one donor. The donors were requested to wipe skin area with an antiseptic and to collect 
milk by spraying it into sterile 50 ml test tubes (Cellstar, Greiner-Bio One GmbH, 
Frickenhausen, Germany) avoiding skin contact. The fresh milk was screened for LAB 
within hours of collection. (Paper I). 
 
Seven dog breeds (German Shephard, Golden Retriever, Jack Russell Terrier, Dachshund, 
German Shorthaired Pointer, Border Collie and a mixed breed) were selected on the basis 
of registration statistics in the USA (Anonymous, 2002a) and in Scandinavia (Anonymous 
2002b, Anonymous, 2002c) in conjunction with the Fédération Cynologique 
Internationale (FCI) breed nomenclature group (Anonymous, 2002d). Faecal samples 
from three healthy individuals from each breed were collected fresh in southern Finland in 
sterile 50 ml tubes (Cellstar, Germany). Information was compiled on the breed, year of 
birth, health condition, medication and diet (commercial dogfood or homemade food). 
Owners were invited to relate the diet and health of their pet.  (Paper III). 
 
Samples of chicken crop and small intestine of the breed male Ross 208 were obtained 
from Danisco Innovation, Kantvik, Finland. Bacteria were streaked on LBS to pure 
cultures and stored at 4oC. (Paper IV). 
  
 
3.2.2. Growth and nisin production of Lactococcus lactis subsp. lactis LL3 in human 
milk and in infant formula  
L. lactis strain LL3 was examined for its ability to metabolize lactose, an ingredient of 
milk, on carbohydrate-free M17 agar (Oxoid) supplemented with 50 µg/ml of bromocresol 
purple as pH indicator (Merck, Germany) and 2% (wt/vol) lactose, incubated overnight at 
30oC. To observe the capacity of L. lactis strain LL3 to grow in infant formula (Tutteli, 
Valio Ltd, Finland) and in human milk, these were seeded with 1.5 × 107 cfu/ml and 
incubated aerobically without shaking for overnight at 30oC. The early lactational 
breastmilk stored at –20oC was thawed and then heated for 10 minutes at 70oC in a water 
bath to inactivate the microbiota. The strain LL3 was grown overnight at 30oC in M17G 
broth (Oxoid) containing 0.5% (wt/vol) of lactose. Growth was recorded in four replicate 
assays. (Paper I). 
 
To test whether or not the antibacterial activity of the L. lactis strains identified in this 
study were nisin, a GFP-based nisin bioassay (Reunanen and Saris, 2003) was employed. 
In this bioassay, nisin was identified and quantified with fluorescence correlated with the 
nisin concentration in the samples. For this, the strains were grown in M17G broth 
containing 5 µg/ml of erythromycin (Erm), 0.1% Tween80 and LAC240 as an indicator 
strain for overnight at 30oC. Fluorescence (excitation 485 nm, emission 538 nm) was 
detected in terms of relative fluorescence units (RFU) with a Fluoroskan Ascent 374 
scanning fluorometer (Labsystems, Helsinki, Finland), computer-linked with Ascent 
version 1.2 software (Labsystems). Viable count for all strains was measured on M17G 
plates (48 h, 30oC) before quantifying nisin production. 
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3.2.3. Fermenting soymilk with L. lactis LL3 and L. lactis ATCC11545 
L. lactis strains LL3 and ATCC11545 were grown overnight at 30oC in M17G (Oxoid,) 
containing 0.5% (w/v) of glucose and then subcultured twice in UHT-treated unsweetened 
soymilk (Tofuline, Carlshamn Mejeri, Sweden) at an inoculation ratio of 1:40. L. lactis 
LL3 and L. lactis ATCC11545 (2.25 x 108 cfu/ml) were separately added with strawberry 
purée (1:100) into sweetened (3.5% glucose) and unsweetened (1.5% glucose) soymilk 
and left to ferment aerobically (stationary) overnight at 30oC. After adding the L. lactis 
inoculum and before ferenting, the pH of the mixture was 6.5. The strawberry purée 
consisted of fresh strawberries cooked with sucrose (30% w/v), jarred aseptically and 
stored at 6oC. The fermented products were cooled to 6oC and shelved at 6oC for three 
weeks. A survey was conducted to compare the consumer palatability and acceptability of 
the fermented soymilk (sweetened, Tofuline) products made with L. lactis strains LL3 and 
ATCC11545 and strawberry purée. Both products were refrigerated at 6oC overnight 
before serving. (Paper II). 
 
 
3.2.4. Acid and intestinal content tolerance of lactic acid bacteria isolated from 
canine faeces 
Tolerance to acidity at pH values 2, 4, and 7 was tested using survival at pH 5.7 (normal 
pH of mLBS broth) as reference. The acidity of mLBS was adjusted using 37% 
hydrochloric acid (Merck). Strains were cultivated in the presence of air at 30oC for 0, 2, 
4, 8, 24 hours. Cross-inhibition was tested by cross-streaking each strain over each other 
on a mLBS plate and then grown overnight aerobically at 30oC. (Paper III). 
 
 
3.2.5. Growth characterization of Lactobacillus crispatus strains 
Resistance to erythromycin (Sigma Chemical Co, St. Louis, MO, USA) and to nisin 
(Sigma Chemical Co, St. Louis, MO, USA) as well as the sensitivity to glycine (Merck, 
Darmstadt, Germany) and growth under aerobic conditions in MRS broth (Becton 
Dickinson Microbiology System, Cockeysville, MD, USA) were measured as an increase 
of OD600 (Lambda Bio UV/VIS spectrophotometer, PerkinElmer Inc, Boston, MA, USA). 
(Paper IV). 
 
 
3.2.6. Electrotransformation of poultry originated L. crispatus  
Transformation of genetic material by electroporation has been successfully employed 
with a number of bacterial species (Argnani et al., 1996; Holo and Nes, 1989; Serror et al., 
2002). Electrotransformation is based on exposing log phase bacterial cells to electric 
pulse in order to porate the cell membrane. Since Gram-positive bacteria possess a thick 
cell membrane, glycine is employed in growth medium to weaken the membrane allowing 
the porous membrane genetic material, such as plasmids, to enter the cell. Bacteria are 
cultivated in recovering broth for several hours before plating on a selective medium 
(Sambrook et al., 1989b).  
 
To initiate electroporation, an overnight culture of L. crispatus was diluted to 1% in fresh 
MRS broth and then grown again for eight hours at 37oC. Subculturing was repeated in 
MRS broth supplemented with 0.8% (w/v) glycine and harvested at OD600 of 0.3-0.4 by 
centrifugation at 9000 × g (10 min, 4oC). The cells were washed twice in ice-cold 
electroporation buffer (0.5 M sucrose, 7 mM KPO4, 1 mM MgCl2, pH 7.4), resuspended in 
electroporation buffer to 1/100 of the original culture volume and stored on ice for a 
maximum of one hour. Plasmids were transformed into the L. crispatus strains as follows: 
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50 µl of cell suspension and 500 ng of plasmid DNA were pipeted into 2 mm 
interelectrode-gap cuvettes (BTX CuvettesTM, San Diego, USA) and a 1.5 kV pulse (200 
Ω, 25 µF) was then applied to the cells (Gene PulserTM and Pulse Controller, Bio-Rad 
Laboratory, Richmond, USA). Cells were then incubated in 2 ml of MRS broth amended 
with 2 mM CaCl2 and 20 mM MgCl2 for three hours at 37
oC. The cells containing 
plasmids were picked from MRS agar with 5 µg of erythromycin /ml and cells with nisin 
selection were picked from MRS agar with 100 IU nisin /ml after three days of growth at 
37oC. Negative controls without the plasmid DNA were similarly cultivated. Transformed 
colonies taken from the plates were placed in MRS broth with erythromycin for plasmid 
isolation. For analysis of the L. crispatus transformants, plasmids were isolated and 
retransformed into CaCl2-treated E. coli TG1 cells due to the better plasmid quality when 
harvested from E. coli. The electrotransformed plasmids were analyzed on 1% agarose gel 
(BioCell Products Oy, Helsinki, Finland). (Paper IV). 
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4. Results and discussion 
 
4.1. Isolation of lactic acid bacteria from human, canine and poultry sources 
The human GI tract has been estimated to contain several hundred species of cultivatable 
bacteria (Moore and Holderman, 1974; Goldin, 1990), of which lactobacilli are 
numerically a minority (Tannock, 1990). Lactobacilli are thought to represent 0 - 2.4% of 
the human microbiota (Brown, 1977; Hove et al., 1999). Sghir et al. (2000) reported the 
amount of Lactobacillus sp. in human faeces is less than 2%. Molecular analysis 
demonstrates that individual humans differ in their microbiota (Favier et al., 2002; Kimura 
et al., 1997; McCartney et al., 1996). The faecal microbiota of monozygotic twin siblings 
were reported to be more similar than those of dizygotic twins (van de Merwe et al., 
1983). In the view of the large inter-individual differences in the microbiota of human 
(Kimura et al., 1997), a single probiotic strain may not be equally effective in all 
individuals (Simmering and Blaut, 2001). 
 
We isolated lactococci from human milk. In order to find LAB with antagonistic 
properties, we used on LB agar overlaid with M. luteus A1 NMIB86166 (Tramer and 
Fowler, 1964). Bacterial strains were selected from 20 samples of human milk based on 
large inhibition zones on agar diffusion plates. Seven samples of milk from six different 
mothers yielded strains with strong antibacterial activity M. luteus A1 NMIB86166. The 
bacterial count of this milk varied between 2 × 102 and 8.7 × 104 cfu/ml (average 1.4 × 
103 cfu/ml). Of these, 30% displayed consistent antagonistic activity against M. luteus and 
tested positive when assayed for nisin using the specific gfp bioassay (Reunanen and 
Saris, 2004). Previously only few bacteriocin-producing LAB species have been isolated 
from human and animal microbiota (Robredo and Torres, 2000; West et al., 1979). Only a 
single nisin-producing L. lactis strain has appeared in human milk, (Heikkilä and Saris, 
2003). The reason for higher counts of nisin-producing L. lactis in this study possibly 
derive from the plating technique, the plates used in previous studies being less favorable 
for isolating nisin-producing L. lactis strains.  
 
Here, the lactobacilli from dog faeces were isolated on modified Lactobacilli Selective 
agar (mLBS) without acetic acid, a medium chosen for its superior selective properties 
(Benno et al., 1992; Gilliland et al., 1975). Plating faeces samples on LBS amended with 
acetic acid yielded no colonies, while plating on LBS without acetic acid did. Other 
selective media have been used, resulting in low amounts of LAB (Dahlinger et al., 1997). 
Also non-LAB species, such as Pediococci sp. and Weissella sp, survived on the medium 
with no acetic acid in our study. Of the 21 investigated samples of canine faeces, 14 
(67%) contained culturable LAB, the amounts averaging 5.8 × 105 ± 2.1 × 105 cfu/g of 
wet faecal matter. The faeces of all tested dog breeds contained LAB with the exception 
of the Dachshund. An explanation for the lowered acid tolerance in the growth medium 
may be the shorter passage time in the canine intestine (Wingfield and Twedt, 1986) when 
compared to the human (Tortora and Grabowski, 1996).  
 
L. crispatus strains from chicken crop and intestine were isolated on LBS agar (Apajalahti 
et al., 2001). Nine isolates were selected for study by electrotransformation with the type 
strain L. crispatus ATCC33820. A variety of Lactobacilli sp. has previously been isolated 
from chicken (Fuller and Brooker, 1974; Gilliland et al., 1975; Jin et al., 1996), L. 
crispatus being one of the identified strains (Edelman et al., 2002; Todoriki et al., 2001; 
van der Wielen et al., 2002). 
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We found LAB in human milk and among the intestinal microbiota of chicken and dog. 
Mammalian neonates receive their microbiota primarily in labor and later from the 
environment (Edwards and Parrett, 2002; Fuller, 1989; Fuller and Gibson, 1998; 
Metchnikoff, 1908), whereas LAB enter the GI tract of poultry soon after hatching and 
adhere to the crop ephitelium throughout the life of the bird (Fuller, 1973). Chicks receive 
bacteria from the eggshell and the environment (Fuller, 1973) but are also fed bacterial 
preparation from adult intestinal microbiota to protect against pathogens, such as 
Salmonella (Nurmi and Rantala, 1973). LAB and bifidobacteria dominate the microbiota 
of the mammalian neonate, especially when breast-fed (Edwards and Parrett, 2002; 
Lönnerdal, 2000), with a health-promoting effect on the child (Arici et al., 2004; Boris et 
al., 1998; Edwards and Parrett, 2002). A study comparing the properties of LAB 
originating in fermented food with those in the GI tract showed that strains are able to 
attach in vitro to human enterocyte-like epithelial cells (Caco-2 cell line) and survive low 
pH and the presence of bile (Haller et al., 2001). The bacterial biota of the GI tract varies 
during first five months of an infant’s life (Heilig et al., 2002) while in the adult the 
genera present is stable (Heilig et al., 2002), changing only with age (Savage, 1977). The 
strain composition varies between individuals (McCartney et al., 1996) as the results of 
Papers I and IV demonstrate. Microbiota shed from the bacteria-colonized intestinal 
epithelium can be detected throughout the GI tract (Tannock, 1990) and in faeces (Savage, 
1977), indicating that LAB isolated from canine faeces have survived the GI tract of the 
host dog (Paper IV). 
 
 
4.2. Identification of isolated strains of lactic acid bacteria 
4.2.1. Genetic characterization of L. lactis and Lactobacillus sp. 
Molecular methods are important for bacterial identification (Drancourt et al., 2000; 
Greetham et al., 2002; Heilig et al., 2002; Sghir et al., 2000) and possibly more accurate 
for LAB than are conventional phenotypic methods. In this study, a 600-900 bp segment 
of the 16S rRNA gene of the LAB isolates was sequenced and the sequence compared to 
strains in the National Center for Biotechnology Information (NCBI) Blast Library as well 
as to those of the respective type strains and to each other. Sequencing results revealed 
that six out of the 20 isolates obtained from the 20 investigated human milk samples were 
Lactococcus lactis (Table 6) with antimicrobial properties. Human milk contains bacteria 
(Pittard et al., 1991), mainly staphylococci and streptococci (Carrol et al., 1979; Eideman 
and Szilagyi, 1979; Heikkilä and Saris, 2003; West et al., 1979) and also LAB (Heikkilä 
and Saris, 2003; Martín et al., 2003). We found that nisin-producing strains of L. lactis 
were frequent in human milk (Paper I). The origins and functions of these L. lactis strains 
remain speculative, but the maternal skin has been proposed as a source (Carroll et al., 
1979; Eideman and Szilagyi, 1979; Martín et al., 2003).  
 
LAB were found in 67% of canine faeces samples (n = 171) (Paper IV). Based on the 16S 
rRNA gene sequence, the canine isolates were identified as Lactobacillus rhamnosus (n = 
27, 16.2%), Weissella confusa (n = 27, 16.2%), Pediococcus acidilactici (n = 26, 15.6%), 
Lactobacillus casei (n = 21, 12.6%) and Lactobacillus salivarius (n = 18, 10.8%) as well 
as other species (n = 48, 28.6 %). The sequence similarities are shown in Table 6. Of the 
species isolated in this study, L. salivarius, L. reuteri and L. murinus were reported in 
canine faeces also by other authors (Fujisawa and Mitsuoka, 1996; Greetham et al., 2002). 
As far as is known, this thesis and Paper IV represent the first report of L. rhamnosus, W. 
confusa, P. acidilactici, L. casei, L. mucosae and L. fermentum in canine faeces.  
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All isolated LAB of chicken origin were identified as Lactobacillus crispatus (Paper III). 
Phylogenetic trees of L. crispatus strains based on partial 16S rRNA sequences (TreeTop 
– Phylogenetic Tree Prediction analyzed with pair distance (Blosum62, Anon, 2003)) and 
whole cell fatty acid analysis (Paper III) revealed a close relation between the L. crispatus 
strains from chicken crop and intestine (Table 6). L. crispatus has  also been reported in 
poultry intestine in several other studies (Sarra et al., 1985; van der Wielen et al., 2002).  
 
 
Table 6. Species identification based on partial (600 to 900 bp) 16S rRNA gene sequence 
comparison. The obtained sequences were compared to those of the respective type strains 
in NCBI Blast Library (www.ncbi.nlm.nih.gov). Nucleotide sequence accession numbers 
for the partial 16S rRNA gene sequences (EMBL, Germany) and the origins of the strains 
are given.  
 
Strain Similarity %  Accession number Strain origin 
Lactococcus lactis LL3  
(DSM14456, HAMBI2371) 
99.8 AJ419572 Human milk 
Lactococcus lactis 310 99  Human milk 
Lactococcus lactis 2410 99  Human milk 
Lactococcus lactis 3A 99  Human milk 
Lactococcus lactis 4B 99  Human milk 
Lactococcus lactis 6A 99  Human milk 
Lactococcus lactis 6B 99  Human milk 
Lactobacillus crispatus 28mc 99 AJ421221 Chicken cecum 
Lactobacillus crispatus 145mc Nd  Chicken cecum 
Lactobacillus crispatus 29mi Nd  Chicken ileum 
Lactobacillus crispatus 81mi Nd  Chicken ileum 
Lactobacillus crispatus 101mi 99 AJ421222 Chicken ileum 
Lactobacillus crispatus 119mi 97.8 AJ421223 Chicken ileum 
Lactobacillus crispatus 134mi 99 AJ421224 Chicken crop 
Lactobacillus crispatus A33 100 AJ421225 Chicken crop 
Lactobacillus fermentum LAB8 
(DSM16347, HAMBI2670) 
99  Canine faeces 
Lactobacillus mucosae LAB12 
(DSM16355, HAMBI2674) 
97  Canine faeces 
Lactobacillus rhamnosus LAB11 
(DSM16349 , HAMBI2673) 
98  Canine faeces 
Lactobacillus salivarius LAB9 
(DSM16357, HAMBI2671) 
97  Canine faeces 
Weissella confusa LAB10 
(DSM16348, HAMBI2672) 
97  Canine faeces 
 
Nd  = Not determined here. Strain sequence results obtained from Danisco-Cultor Ltd. 
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4.2.2. Antimicrobial activity of L. lactis isolated from human milk  
Many different antimicrobial peptides, most commonly nisin, have been found in strains 
of L. lactis (Barefoot and Nettles, 1993; McAuliffe et al., 2001). We investigated isolates 
of L. lactis from human milk for their potential to produce nisin. The GFP based nisin 
bioassay (Reunanen and Saris, 2003) was employed for this purpose. In this bioassay, 
nisin is identified and quantified by fluorescence which is proportional to the 
concentration of nisin in the samples. We found that all human L. lactis isolates produced 
nisin (Paper I). The strain LL3 grew in heat-treated human milk and in UHT-treated infant 
formula at 30oC (Fig. 2), producing 3.75 µg nisin /ml  and 5 µg nisin /ml respectively 
overnight. The quantities are sufficient to inhibit a number of pathogens (Thomas et al., 
2000). Differences in strain growth in both types of milk after 24 h were not significant. 
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Figure 2. Growth of Lactococcus lactis LL3 of human origin in human milk (♦) and in
infant formula (■) (Tutteli, Valio Ltd, Helsinki, Finland) at 30oC. Data points and standard 
errors represent averages of four replicates. 
 
 
LAB strains of canine origin did not inhibit each other when cross-streaked on LBS agar. 
Also no antimicrobial effect was observed towards M. luteus A1 NCIMB86166 in the agar 
diffusion test (Paper IV). The five tested LAB strains demonstrated the capability to grow 
among each other, offering potential additive or synergistic probiotic impacts. A probiotic 
product including several strains provides a faster strain growth rate due to the superior 
performance of energy generation (Centeno et al., 2002) and offers a wider health benefit 
than would a single strain. Greetham et al. (2002) concluded that the lactobacilli isolated 
from canine faeces possibly constitute competitive exclusion to the benefit of the canine 
host.  
  
 
4.2.3. Genetic characterization of the strains of L. lactis and Lactobacillus found in 
human milk  
The seven nisin-producing strains of L. lactis isolated from human milk were compared 
by Riboprinting analysis to the L. lactis strains ATCC11454 and N8 producing nisin A or 
nisin Z, the two natural nisin variants existing in food. The ribopatterns obtained with 
EcoRI and PvuII enzymes of the isolates of human milk formed a cluster (Paper I, Fig. 1). 
The nisin producers of human origin differed from the strains producing nisin A and nisin 
Z isolated from cow milk. When the resulting fragment sizes from the two enzymes were 
combined and analyzed using the UPGMA algorithm, the human isolates clustered 
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separately from the respective type strains and strain N8. Sequencing to determine the 
nisin variant of the nisin structural gene of the L. lactis strain LL3 revealed it to be a nisin 
A producer (Paper I). 
  
 
4.2.4. Strain characterization of the isolated lactic acid bacteria 
Nisin-producing L. lactis strain LL3 was examined for its ability to metabolize lactose, an 
ingredient of milk and infant formulas. The use of other carbohydrates was screened to 
determine if strain LL3 grew in growth media other than human milk. (Paper I). When L. 
lactis LL3 was added as a protective culture to infant formulas (Gupta et al., 2000; Hurst 
and Hoover, 1993; Lee et al., 2003; Thomas et al., 2000; Zapico et al., 1998), it used 
lactose for growth. L. lactis LL3 fermented nine monosaccharides, six disaccharides and 
some amino sugars and glycosides, indicating that strain LL3 can ferment soymilk, a 
milk-like vegetable product. (Paper I). Soymilk is high in protein but also contains sucrose 
(Mital and Steinkraus, 1974), a disaccharide which L. lactis LL3 fermented (Paper I). 
Fermentation of soymilk is also known to mask its unappealing flavor (Mital and 
Steinkraus, 1974).  
 
L. fermentum, L. mucosae, L. rhamnosus, L. salivarius and W. confusa of canine origin 
were found to be oxygen tolerant: the average culture density in mLBS broth reached an 
OD600 of 1.4 (6.3 × 10
9 cfu/ml) within 12 hours of aerobic cultivation. L. rhamnosus 
achieved higher densities OD600 (1.6, 5.4 × 10
9 cfu/ml) in 12 hours at 30oC, whereas L. 
rhamnosus LAB11 incubated without oxygen rose to 4.1 × 109 cfu/ml in identical 
incubation conditions. (Paper IV). Stable and strong growth is desirable for the 
technological use of health-promoting bacteria (Charteris et al., 1998a; Knorr, 1998). The 
ambient concentration of oxygen did not effect the growth of the LAB strains isolated in 
this thesis, suggesting viability during the oxic phases of an industrial process. In order to 
survive until reaching the small intestine, probiotic bacteria must tolerate passage at low 
pH in the stomach. With this in mind, the five canine LAB strains were inoculated in 
mLBS to a density  106 to 108 cfu/ml and incubated for 24 hours aerobically at pH 2, 4, 
5.7 and 7 at 30oC. All strains thrived in conditions of pH ≥ 4. In addition, L. salivarius 
LAB8 and W. confusa LAB10 survived and grew to >105 cfu/ml within eight hours at pH 
2, indicating that these acid-tolerant strains have a better chance of surviving the GI tract 
and thus show probiotic potential by being able to thrive in an industrial environment. L. 
mucosae LAB12 survived four hours at pH 2, while strains L. fermentum LAB8 and L. 
rhamnosus LAB11 did not survive longer than two hours when exposed to pH 2. (Paper 
IV). Acid tolerance was also reported for two Lactobacillus brevis strains taken from 
chicken ileum by Jin et al (1998), which tolerated pH 2 for three hours and survived for 
two hours even at pH 1.  
 
The aerobic growth of L. crispatus strains was studied. Those tolerant to oxygen (28mc, 
145mc, 29mi, 101mi, 119mi, 134 and A33) were investigated for sensitivity to 
erythromycin (1 µg of Erm /ml), nisin (10 IU of nisin /ml) and glycine (0.5 - 2%). These 
characteristics were required to monitor for tolerance to electrotransformation. Five 
Lactobacillus strains were selected for electrotransformation based on their resistance to 
0.5% glycine and sensitivity to antimicrobials. (Paper III). Glycine in the growth medium 
has been reported to weaken the cell wall of Gram-positive bacteria in a dose-dependent 
manner (Holo and Nes, 1989; Thompson and Collins, 1996) and therefore aid 
electroporation. 
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4.3. Exploiting the novel isolates of lactic acid bacteria 
In light of the documented biochemical, physiological and immunological influence of the 
GI microbiota on the host and its resistance to disease, the selection of health-promoting 
bacteria must rest on the documented impacts of selected probiotic strains on the 
microbial community harbored within the digestive tract (Tannock, 1998). These aspects 
are discussed below. Probiotics promote health in humans and animals through their 
presence in foodstuffs or pharmaceutical products (Bernet-Camard et al., 1997; Canducci 
et al., 2000; Gilliland et al., 1985; Gionchetti et al., 2000; Fooks et al., 1999; Heyman, 
2000; Joosten et al., 1996, Kuisma et al., 2003; Nurmi and Rantala, 1973; Ryan et al., 
1996; Ryan et al., 1998; Schaafsma et al., 1998). 
 
 
4.3.1. Nisin-producing L. lactis LL3 of human origin improving the microbiological 
safety of infant formula 
The protective property of 107 cfu/ml of L. lactis LL3 added to an infant formula was 
investigated in vitro against the toxin-producing Bacillus licheniformis 553/1 (Mikkola et 
al., 2000), as a consequence of a fatal food poisoning concerning an infant (Salkinoja-
Salonen et al., 1999). We found that the strain LL3 inhibited the germination of B. 
licheniformis 553/1 spores and vegetative growth for 24 hours in an infant formula spiked 
with spores (102 cfu/ml) or vegetative cells (104 cfu/ml). L. lactis strains LL3 and 
NZ9800, a reference strain not producing nisin, were observed to multiply up to a 
hundred-fold aerobically in infant formula at 22oC and at 37oC in 24 h. In the presence of 
L. lactis NZ9800, B. licheniformis 553/1 displayed a lag phase of ≥ 6 hours before starting 
to grow in the formula. The number of vegetative cells of B. licheniformis 553/1 declined 
four log units in two hours, presumably due to the acid production of L. lactis NZ9800 
and the consistency of the infant formula. When infant formula was inoculated with L. 
lactis LL3, B. licheniformis 553/1 declined to below the detection limit (<10 cfu/ml) in 
two hours and then remained at this level (Fig. 3). Nisin (1.25 µg/ml) was detected after 
two hours of incubation of the strain LL3 in formula. In eight hours at 37oC, the nisin 
concentration had reached 2.5 µg/ml. These data demostrate that the inhibition of B. 
licheniformis 553/1 by L. lactis LL3 was due to nisin. Mansour et al. (1999) reported the 
inhibition of B. licheniformis in milk through the combination of nisin, monolaurin and 
pH 6. To increase shelf life of pasteurized dairy products significantly, 0.625 to 1.25 
µg/ml of purified nisin was required (Delvis-Broughton et al., 1996), whereas 2.5 µg/ml 
was needed to inhibit the growth of B. cereus (Nissen et al., 2001). Our results indicate 
that L. lactis LL3 produced nisin concentrations sufficient to protect this dairy product 
against B. licheniformis, commonly present in infant formula as a contaminant (Rowan 
and Anderson, 1998).  
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Figure 3. Growth of heat-stable toxin-producing strain of Bacillus licheniformis 553/1 in 
the presence of Lactococcus lactis LL3 in a commercial UHT-treated liquid infant 
formula (Tutteli, Valio Ltd, Helsinki, Finland). Inoculum was vegetative (A) B. 
licheniformis 553/1 or spores (B) of B. licheniformis 553/ grown at 37oC. A nisin non-
producer strain of L. lactis NZ9800 served as a negative control. Black columns (no L. 
lactis); gray columns (L. lactis NZ9800); white columns (L. lactis LL3).  
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Many infants will consume nisin-producing L. lactis bacteria during breastfeeding (Paper 
I). Imbibing human milk containing nisin producers may positively affect infant health if 
nisin producers survive and if nisin is produced at levels inhibiting pathogens (Breukink 
and de Kruijff, 1999; Elliason and Tatini, 1999; Hurst and Hoover, 1993; Thomas et al., 
2000; Zapico et al., 1998) in the digestive tract (Klijn et al., 1995; Drouault et al., 1999). 
Since L. lactis LL3 found in human milk is able to grow and produce nisin in infant 
formula and inihibits the growth of toxin-producing B. licheniformis 553/1 within two 
hours of inoculation (Paper I), this characteristic could be exploited by employing the 
nisin-producing L. lactis LL3 strain of human origin as an infant food protective culture 
against pathogens. Furthermore, nisin-producing L. lactis potentially protects mothers 
from mastitis and infants from infection by such pathogens as Staphylococcus aureus 
(Pittard et al., 1991). The effect of nisin producers on the microbiota of the human 
gastrointestinal tract remains to be clarified. Nisin producers might survive in the GI tract 
of human (Klijn et al., 1995) and of mouse (Drouault et al., 1999), but it is not known if 
nisin is produced in the intestine. 
 
 
4.3.2. Nisin-producing L. lactis LL3 of human origin as a yoghurt starter 
We used L. lactis strain LL3 isolated from human milk (Paper I) to ferment soymilk in 
parallel with L. lactis ATCC11545 originating from cow milk to determine if L. lactis 
LL3 can grow in soymilk and produce a palatable product for vegetarians or those allergic 
to milk. Both L. lactis strains survived at densities of > 108 cfu/ml during a three-week 
shelving of sweetened and non-sweetened UTH-treated soymilk at 6oC, despite a transient 
decline in L. lactis levels during the second week of storage. Adding glucose and/or 
strawberry purée to soymilk accelerated the growth of the L. lactis strains (Paper II). Chou 
and Hou (2000) and Rossi et al. (1999) also observed that soymilk with added 
carbohydrates supported the growth of several lactic acid bacteria cultured together. After 
ensuring adequate survival of the fermenting bacteria, the microbiological safety and the 
stability of the soymilk product was investigated (Paper II). No coliform bacteria, yeasts 
or molds were detected (<10 cfu/ml) except in one batch of sweetened soymilk with 1% 
strawberry purée where yeast and mold were detected at levels of 50 cfu/ml. The density 
of non-starter bacteria remained below 350 cfu/ml (± SD of 90 cfu/ml) after three weeks 
of storage, indicating good hygienic standard. The pH and sensory characteristics were 
stable throughout the three-week shelving period, with pH remaining at 4.4 on average 
and above 4.2 at all times. The density of L. lactis LL3 was stable in soymilk over the 
three-week shelf life at 6oC. A consumer survey was conducted at a food fair to compare 
the acceptability of the products fermented with L. lactis strain LL3 (human milk isolate) 
and ATCC11545 (originating from cow milk). In blind sampling, the two strains were 
rated equally attractive, whereas information on the origin of the LL3 product 
significantly enhanced its perceived pleasantness. (Paper II). 
 
This thesis was the first to demonstrate the use of LAB isolated from human milk as a 
starter in food processing. The consumer survey demonstrated the positive attitude 
towards the origin of the starter, indicating that strains taken from human milk would be 
an acceptable source as a new starter or probiotic strain. These properties show potential 
for use as a health product for lactose-intolerant consumers, vegetarians and milk-allergy 
patients. Additionally, soymilk is free of cholesterol, gluten and lactose (Liu and Lin, 
2000). The nutritive quality of soybean protein stands at the pinnacle of the food chain 
available in the plant world. The phytoestrogens in soy have been found to stimulate the 
clearance of cholesterol by up-regulating low-density lipoprotein (LDL) receptors, thereby 
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increasing LDL receptor activity (Tham et al., 1998) and so augmenting the health-benefit 
values of soy. 
  
Our study showed that the monoculture of L. lactis LL3 was  enough to stabilize the 
flavor of the product, leading to high ratings for “pleasantness” in taste and texture from a 
consumer tasting panel. A monoculture adapts better to industrial processes than 
multicomponent cultures, such as combinations of Enterococcus faecium, Lactobacillus 
acidophilus, L. jugurti, L. delbrueckii ssp. bulgaricus and Streptococcus thermophilus 
added to soymilk (Rossi et al., 1999). Soymilk is a good medium for bacteria capable of 
fermenting  sucrose and raffinose oligosaccharides, mainly raffinose and stachyose 
(Scalabrini et al., 1998). When raffinose oligosaccharides are passed into the large 
intestine, anaerobic microorganisms ferment them to cause flatulance (Guimarães et al., 
2001). High-protein soymilk has also been shown to lower cholesterol when soybean 
protein completely replaces the proteins in cow milk (Sitrori et al., 1999). However, 
soymilk also contains a trypsin inhibitor (Bai et al., 1998) which depletes the dietary 
protein digestion in the intestine.  
 
L. lactis LL3 grew in soymilk to produce a palatable and acceptable fermented product. 
The product was microbiologically and flavor stable over the three-week shelf life at 6oC. 
L. lactis LL3 can be used as a monoculture for fermenting soymilk into yoghurt with good 
sensory characteristics.  
 
 
4.3.3. Lactic acid bacteria from healthy dogs 
The LAB strains isolated from canine faeces (L. fermentum LAB8, L. salivarius LAB9, 
W. confusa LAB10, L. rhamnosus LAB11 and L. mucosae LAB12) grew under aerobic 
and anaerobic atmospheres and at pH 4 and above within 48 hours. LAB strains 
demonstrated the capacity to grow with each other, allowing for combined use to provide 
potential complementary or synergistic probiotic effects for dogs. (Paper IV). Since the 
probiotic addition to canine weaning food is thought to promote overall health over the 
dog’s lifespan particularly the development of its immune system (Benyacoub et al., 2003; 
Biourge et al., 1998). Dog foods containing LAB are available in pet stores and from 
veterinarians in Finland (Anon, 2004a; Anon, 2004b). The origins of these LAB have not 
been made public. In the absence of a safe and effective host-specific probiotic product for 
dogs, E. faecium, the sole pharmaceutical probiotic on the commercial market for 
veterinary use in Finland, was reported to increase the adhesion and colonization of 
Campylobacter jejuni on canine intestinal mucus (Rinkinen et al., 2003). LAB isolated 
from canine intestine adhere to immobilized intestinal mucus (Rinkinen et al., 2000) and 
inhibit the adhesion of certain bacterial pathogens (Rinkinen et al., 2003). Some 
enterococcal strains are opportunist pathogens with transferable antibiotic resistance and 
thus are not advised for use as probiotics in food (Sanders, 2003). The need for feeding 
studies is felt for evaluation of the potential probiotic impacts of the strains isolated and 
studied in Paper IV. The LAB strains discussed in Paper IV, present in healthy dogs, may 
possess the technical potential for serving as probiotics for dogs. 
 
 
4.3.4. Electrotransformability of  lactic acid bacteria of poultry origin 
The suitability of L. crispatus strains (28mc, 145mc, 29mi, 101mi, 119mi, 134mi and 
A33) taken from chicken, as well as the type strain ATCC33820 was investigated for 
genetic engineering. Electrotransformation of pLEB579 yielded erythromycin-resistant 
colonies from four strains of L. crispatus, with a transformation frequency of 30 
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transformants per µg of DNA. Transformations were repeated from five to seven times, 
depending on the strain. Strains electrotreated without a plasmid and plated on MRS agar 
containing 5 µg/ml of erythromycin did not yield erm resistant colonies. 
Electrotransformation (from one to seven attempts, depending on the strain) with the 
plasmids (pLEB580, pLEB590, pLEB599 and pNZ9111, their size varying from 3.1 to 
15.4 kb) did not produce colonies, suggesting that the plasmid size had an impact on the 
transformation efficiency (Paper III). In most bacteria, the frequency of electroporation 
generally decreases with the increasing size of the transforming DNA (Gasson and 
Fitzgerald, 1994). A low frequency of transformation among wild-type lactobacilli is 
common (Aukrust and Blom, 1992). In conclusion, wild-type LAB are potentially 
electrotransformable when the DNA transformed is small enough.  
 
Isolation of the plasmid (pLEB579) from the L. crispatus, ermR transformants resulted in 
preparations in which the isolated DNA was extensively degraded (Paper III). For this 
reason, plasmid content analysis of the transformants was performed by transformation of 
the isolated plasmids into E. coli TG-1 from which the plasmids could be isolated without 
degradation. These plasmids were mostly of altered size and, as a rule, larger compared to 
plasmid pLEB579. Only a portion of the plasmids originating from the transformants of 
strains 101mi, 119mi and A33 were of the same size (2.9 kb) as pLEB579. These 
plasmids displayed the Sau3AI restriction pattern identical to pLEB579. The L. crispatus 
strains were observed to rearrange the plasmids efficiently (Fig. 3). To avoid these 
stability problems, expression constructs should aim at integration into the chromosome, a 
more stable location than multicopy plasmids. Our results revealed that genetic 
engineering of L. crispatus of poultry origin was possible (Fig. 3). In spite of the observed 
low frequency, regions of the plasmid, after further analysis, might provide the basis for 
the construction of efficient vectors that could be used to genetically modify strains of L. 
crispatus. 
 
 
 
 
 
 
Figure 3. Rearrangements of selected plasmids electrotransformed into strains of 
Lactobacillus crispatus. A 2,9 kb plasmid (pLEB579) was electrotransformed into L. 
crispatus A33 (lanes 3-12), retransformed and isolated from Escherichia coli TG-1. Lanes 
1, 14: λ Pst marker; lanes 2, 13: pLEB579.   
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L. crispatus strains 134mi and A33 have been reported to adhere to chicken epithelia 
(Edelman et al., 2002). Fuller (1973) demonstrated that lactic acid bacteria adhered to 
chicken intestinal epithelium after hatching, and remain and survived in the intestine 
throughout the life of the chicken (Todoriki et al., 2001), revealing probiotic potential. In 
this thesis, a small plasmid (pLEM579, 2.9 kb) was electrotransformed into four strains of 
L. crispatus isolated from chicken crop and intestine, respectively, using a modified 
transformation method. This method enables the genetic engineering of L. crispatus 
towards poultry strains.  
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5. Summary and conclusions 
 
LAB are present in the microbiota of mammals and birds (Fuller, 1989). This thesis 
describes LAB isolated from human milk and canine faeces as well as from chicken crop 
and intestine. These bacterial strains were characterized and their suitability for 
exploitation charted.  
 
Nisin-producing Lactococcus lactis strains (n = 6) were isolated from 20 samples of 
human milk. The nisin from a high (3.75 µg/ml) producer strain L. lactis LL3 was 
identified as nisin A. This strain ferments lactose contained in all milks and infant 
formulas. L. lactis LL3 displayed good sensory and technical characteristics as a yoghurt 
starter in infant formula. The strain also inhibited a toxin-producing strain of Bacillus 
licheniformis 553/1. The strain LL3 thus shows potential for improving the 
microbiological safety of infant formula. Nisin-producing bacteria were found to be 
naturally present in human milk, and is recognized to be a new protective mechanism for 
human milk. When L. lactis LL3 was used to ferment soymilk, it survived at levels of > 
107 cfu/ml for three weeks in the soymilk. A consumer survey revealed that the 
acceptability of the fermented product was similar to a product made with L. lactis 
ATCC11545 originally isolated from cow milk. In blind sampling, the two strains were 
rated equally attractive, whereas information on the origin of the LL3 product 
significantly enhanced its perceived pleasantness in panel ratings. 
 
Lactic acid bacteria were isolated from the faecal microbiota of healthy dogs in the search 
to find strains for use as canine probiotics. LAB were found in canine faeces when plated 
on an acetic acid-free medium but not on a lactobacilli isolation medium containing acetic 
acid (LBS). LAB appeared in 67% of the canine faeces sampled from the seven most 
popular dog breeds in Finland, Sweden and the USA. The species L. rhamnosus, W. 
confusa, P. acidilactici, L. casei, L. mucosae and L. fermentum were isolated from canine 
faeces for the first time in this research.  Lactobacillus fermentum, Lactobacillus mucosae, 
Lactobacillus rhamnosus and Weissella confusa strains were able to grow with and 
without oxygen and were acid tolerant. No decrease in cell viability of W. confusa was 
observed in a LBS medium at pH 2 within four hours.  
 
Lactobacillus crispatus strains 28mc, 145mc, 29mi, 101mi, 119mi, 134mi and A33 from 
chicken crop and intestine origin and the type strain ATCC33820 were characterized for 
genetic engineering potential. All grew aerobically, were sensitive to erythromycin and 
nisin and were tolerant to glycine. Out of five investigated plasmids, a 2.9 kb plasmid 
(pLEB579) was successfully introduced into four wild-type L. crispatus strains (101mi, 
119mi, 134mi and A33) of chicken origin with a transformation frequency of 30 
transformants per µg of DNA. The frequency was low although sufficient to allow 
bioengineering of these strains.  
 
In this thesis, Lactoccoccus lactis ssp. lactis, Lactobacillus crispatus, Lactobacillus 
fermentum, Lactobacillus mucosae, Lactobacillus rhamnosus and Weissella confusa were 
taken from the gastrointestinal tract and faeces of animals and from human milk, then 
characterized and investigated for their potential as probiotics for their hosts. In 
conclusion, LAB of human and animal origin may serve as bacteria potentially promoting 
host-specific health. 
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